Your request to link to rcsb for BRD4-BD1-BD2

• 2DWW: crystal structure of bromodomain-containing protein 4
• 2I8N: solution structure of the second bromodomain of brd4
• 2LSP: solution structures of brd4 second bromodomain with nf-kb-k310ac peptide (10.1074/JBC.M112.359505 )
• 2MJV: solution structures of second bromodomain of brd4 with di-acetylated twist peptide (10.1016/J.CCR.2014.01.028 )
• 2OSS: crystal structure of the bromo domain 1 in human bromodomain containing protein 4 (brd4) (10.1016/J.CELL.2012.02.013 )
• 2OUO: crystal structure of the bromo domain 2 in human bromodomain containing protein 4 (brd4) (10.1016/J.CELL.2012.02.013 )
• 2YEL: crystal structure of the first bromodomain of human brd4 with the inhibitor gw841819x (10.1021/JM200108T )
• 2YEM: crystal structure of the second bromodomain of human brd4 with the inhibitor gw841819x (10.1021/JM200108T )
• 3JVJ: crystal structure of the bromodomain 1 in mouse brd4 (10.1074/JBC.M109.033712 )
• 3JVK: crystal structure of bromodomain 1 of mouse brd4 in complex with histone h3-k(ac)14 (10.1074/JBC.M109.033712 )
• 3JVL: crystal structure of bromodomain 2 of mouse brd4 (10.1074/JBC.M109.033712 )
• 3JVM: crystal structure of bromodomain 2 of mouse brd4 (10.1074/JBC.M109.033712 )
• 3MUK: crystal structure of brd4 bromodomain 1 with propionylated histone h3- k(prop)23 (10.1002/ANIE.201002724 )
• 3MUL: crystal structure of brd4 bromodomain 1 with butyrylated histone h3- k(buty)14 (10.1002/ANIE.201002724 )
• 3MXF: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jq1 (10.1038/NATURE09504 )
• 3P5O: crystal structure of the first bromodomain of human brd4 in complex with ibet inhibitor (10.1038/NATURE09589 )
• 3SVF: crystal structure of the first bromodomain of human brd4 in complex with a dihydro-quinazolin ligand
• 3SVG: crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand
• 3U5J: crystal structure of the first bromodomain of human brd4 in complex with alprazolam (10.1016/J.BMC.2011.10.080 )
• 3U5K: crystal structure of the first bromodomain of human brd4 in complex with midazolam (10.1016/J.BMC.2011.10.080 )
• 3U5L: crystal structure of the first bromodomain of human brd4 in complex with a benzo-triazepine ligand (bzt-7) (10.1016/J.BMC.2011.10.080 )
• 3UVW: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated histone 4 peptide (h4k5ack8ac) (10.1016/J.CELL.2012.02.013 )
• 3UVX: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated histone 4 peptide (h4k12ack16ac) (10.1016/J.CELL.2012.02.013 )
• 3UVY: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated histone 4 peptide (h4k16ack20ac) (10.1016/J.CELL.2012.02.013 )
• 3UW9: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated histone 4 peptide (h4k8ack12ac) (10.1016/J.CELL.2012.02.013 )
• 3ZYU: crystal structure of the first bromodomain of human brd4 in complex with i-bet151(gsk1210151a) (10.1038/NATURE10509 )
• 4A9L: n-terminal bromodomain of human brd4 with 1,3-dimethyl-6-( morpholine-4-sulfonyl)-1,2,3,4-tetrahydroquinazolin-2-one (10.1021/JM201320W )
• 4BJX: n-terminal bromodomain of human brd4 with gsk1324726a (i-bet726) (10.1371/JOURNAL.PONE.0072967 )
• 4BW1: the first bromodomain of human brd4 in complex with 3,5 dimethylisoxaxole ligand (10.1002/CMDC.201300259 )
• 4BW2: the first bromodomain of human brd4 in complex with 3,5 dimethylisoxaxole ligand (10.1002/CMDC.201300259 )
• 4BW3: the first bromodomain of human brd4 in complex with 3,5 dimethylisoxaxole ligand (10.1002/CMDC.201300259 )
• 4BW4: the first bromodomain of human brd4 in complex with 3,5 dimethylisoxaxole ligand (10.1002/CMDC.201300259 )
• 4C66: discovery of epigenetic regulator i-bet762: lead optimization to afford a clinical candidate inhibitor of the bet bromodomains (10.1021/JM401088K )
• 4C67: discovery of epigenetic regulator i-bet762: lead optimization to afford a clinical candidate inhibitor of the bet bromodomains (10.1021/JM401088K )
• 4CFK: n-terminal bromodomain of human brd4 with ly294002 (10.1021/CB400789E )
• 4CFL: n-terminal bromodomain of human brd4 with ly303511 (10.1021/CB400789E )
• 4CL9: n-terminal bromodomain of human brd4 with i-bet295 (10.1039/C3MD00285C )
• 4CLB: n-terminal bromodomain of human brd4 with ibet-295 (10.1039/C3MD00285C )
• 4DON: brd4 bromodomain 1 complex with a fragment 3,4-dihydro-3-methyl-2(1h)- quinazolinon
• 4E96: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor pfi-1 (10.1021/JM3010515 )
• 4F3I: crystal structure of the first bromodomain of human brd4 in complex with ms417 inhibitor (10.1074/JBC.M112.359505 )
• 4GPJ: crystal structure of the first bromodomain of human brd4 in complex with a isoxazolylbenzimidazole ligand
• 4HBV: crystal structure of the first bromodomain of human brd4 in complex with a quinazolin ligand (10.1021/JM3010515 )
• 4HBW: crystal structure of the first bromodomain of human brd4 in complex with a quinazoline ligand (10.1021/JM3010515 )
• 4HBX: crystal structure of the first bromodomain of human brd4 in complex with a quinazolin ligand (10.1021/JM3010515 )
• 4HBY: crystal structure of the first bromodomain of human brd4 in complex with a quinazolin ligand (10.1021/JM3010515 )
• 4HXK: brd4 bromodomain 1 complex with 6,7-dihydrothieno[3,2-c]pyridin-5(4h)- yl(1h-imidazol-1-yl)methanone inhibitor (10.1021/JM301793A )
• 4HXL: brd4 bromodomain 1 complex with 3-cyclohexyl-n-{3-(2-oxo-2,3-dihydro- 1,3-thiazol-4-yl)-5-[(thiophen-2-ylsulfonyl)amino]phenyl}propanamide inhibitor (10.1021/JM301793A )
• 4HXM: brd4 bromodomain 1 complex with n-{3-(2-oxo-2,3-dihydro-1,3-thiazol-4- yl)-5-[(thiophen-2-ylsulfonyl)amino]phenyl}butanamide inhibitor (10.1021/JM301793A )
• 4HXN: brd4 bromodomain 1 complex with 4-(2-fluorophenyl)-1,3-thiazol-2(3h)- one inhibitor (10.1021/JM301793A )
• 4HXO: brd4 bromodomain 1 complex with 3-{[(3-methyl-1,2-oxazol-5-yl) methyl]sulfanyl}[1,2,4]triazolo[4,3-a]pyridine inhibitor (10.1021/JM301793A )
• 4HXP: brd4 bromodomain 1 complex with 4-(2-oxo-1,3-oxazolidin-3-yl)benzamide inhibitor (10.1021/JM301793A )
• 4HXR: brd4 bromodomain 1 complex with n-[3-(2-oxo-2,3-dihydro-1,3-thiazol-4- yl)phenyl]thiophene-2-sulfonamide inhibitor (10.1021/JM301793A )
• 4HXS: brd4 bromodomain 1 complex with n-[3-(2-oxo-2,3-dihydro-1,3-thiazol-4- yl)phenyl]-1-phenylmethanesulfonamide inhibitor (10.1021/JM301793A )
• 4IOO: crystal structure of the first bromodomain of brd4 in complex with n- methyltrimethylacetamide (10.1107/S090744491301994X )
• 4IOQ: crystal structure of the first bromodomain of brd4 in complex with pyrrolidin-2-one (10.1107/S090744491301994X )
• 4IOR: crystal structure of the first bromodomain of brd4 in complex with dmso (10.1107/S090744491301994X )
• 4J0R: crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand (10.1021/JM301588R )
• 4J0S: crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand (10.1021/JM301588R )
• 4J3I: x-ray crystal structure of bromodomain complex to 1.24 a resolution (10.1371/JOURNAL.PONE.0083190 )
• 4KV1: crystal structure of brd4 bromodomain 1 in complex with acetylated rel peptide (10.1038/ONC.2013.179 )
• 4KV4: brd4 bromodomain 2 in complex with acetylated rel peptide (10.1038/ONC.2013.179 )
• 4LR6: structure of brd4 bromodomain 1 with a 3-methyl-4-phenylisoxazol-5- amine fragment (10.1021/ML4001485 )
• 4LRG: structure of brd4 bromodomain 1 with a dimethyl thiophene isoxazole azepine carboxamide (10.1021/ML4001485 )
• 4LYI: crystal structure of apo-brd4(1) (10.1002/ANIE.201307652 )
• 4LYS: crystal structure of brd4(1) bound to colchiceine (10.1002/ANIE.201307652 )
• 4LYW: crystal structure of brd4(1) bound to inhibitor xd14 (10.1002/ANIE.201307652 )
• 4LZR: crystal structure of brd4(1) bound to colchicine 29-jan-14 4lzr 1 title (10.1002/ANIE.201307652 )
• 4LZS: crystal structure of brd4(1) bound to inhibitor xd46 (10.1002/ANIE.201307652 )
• 4MEN: crystal structure of the first bromodomain of human brd4 in complex with a 5-methyl-triazolopyrimidine ligand (10.1021/JM4011302 )
• 4MEO: crystal structure of the first bromodomain of human brd4 in complex with a 2-methyl-quinoline ligand (10.1021/JM4011302 )
• 4MEP: crystal structure of the first bromodomain of human brd4 in complex with a 3-chloro-pyridone ligand (10.1021/JM4011302 )
• 4MEQ: crystal structure of the first bromodomain of human brd4 in complex with a 5-methyl-triazolopyrimidine ligand (10.1021/JM4011302 )
• 4MR3: crystal structure of the first bromodomain of human brd4 in complex with a quinazolinone ligand (rvx-oh) (10.1073/PNAS.1310658110 )
• 4MR4: crystal structure of the first bromodomain of human brd4 in complex with a quinazolinone ligand (rvx-208) (10.1073/PNAS.1310658110 )
• 4NQM: crystal structure of the first bromodomain of human brd4 in complex with a triazolo-phthalazine ligand
• 4NR8: crystal structure of the first bromodomain of human brd4 in complex with an isoxazolyl-benzimidazole ligand
• 4NUC: crystal structure of the first bromodomain of human brd4 in complex with ms435 inhibitor
• 4NUD: crystal structure of the first bromodomain of human brd4 in complex with ms436 inhibitor
• 4NUE: crystal structure of the first bromodomain of human brd4 in complex with ms267 inhibitor
• 4O70: crystal structure of the first bromodomain of human brd4 in complex with dinaciclib (10.1021/CB500072Z )
• 4O71: crystal structure of the first bromodomain of human brd4 in complex with flavopiridol (10.1021/CB500072Z )
• 4O72: crystal structure of the first bromodomain of human brd4 in complex with nu7441 (10.1021/CB500072Z )
• 4O74: crystal structure of the first bromodomain of human brd4 in complex with bi 2536 (10.1021/CB500072Z )
• 4O75: crystal structure of the first bromodomain of human brd4 in complex with fostamatinib (10.1021/CB500072Z )
• 4O76: crystal structure of the first bromodomain of human brd4 in complex with tg101209 (10.1021/CB500072Z )
• 4O77: crystal structure of the first bromodomain of human brd4 in complex with sb 202190 (10.1021/CB500072Z )
• 4O78: crystal structure of the first bromodomain of human brd4 in complex with gw612286x (10.1021/CB500072Z )
• 4O7A: crystal structure of the first bromodomain of human brd4 in complex with sb-409514 (10.1021/CB500072Z )
• 4O7B: crystal structure of the first bromodomain of human brd4 in complex with sb-284847-bt (10.1021/CB500072Z )
• 4O7C: crystal structure of the first bromodomain of human brd4 in complex with sb-614067-r (10.1021/CB500072Z )
• 4O7E: crystal structure of the first bromodomain of human brd4 in complex with sb-610251-b (10.1021/CB500072Z )
• 4O7F: crystal structure of the first bromodomain of human brd4 in complex with sb-251527 (10.1021/CB500072Z )
• 4OGI: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor bi-2536 (10.1038/NCHEMBIO.1471 )
• 4OGJ: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor tg-101348 (10.1038/NCHEMBIO.1471 )
• 4PCE: crystal structure of the first bromodomain of human brd4 in complex with compound b13 (10.1016/J.BMCL.2014.04.017 )
• 4PCI: crystal structure of the first bromodomain of brd4 in complex with b16 (10.1016/J.BMCL.2014.04.017 )
• 4PS5: crystal structure of the first bromodomain of human brd4 in complex with tg101348 (10.1021/CB500072Z )
• 4QB3: crystal structure of the first bromodomain of human brd4 in complex with olinone (10.1016/J.CHEMBIOL.2014.05.009 )
• 4QR3: brd4 bromodomain 1 complex with its novel inhibitors (10.1021/JM501504K )
• 4QR4: brd4 bromodomain 1 complex with its novel inhibitors (10.1021/JM501504K )
• 4QR5: brd4 bromodomain 1 complex with its novel inhibitors (10.1021/JM501504K )
• 4QZS: crystal structure of the first bromodomain of human 3-fluoro tyrosine- labeled brd4 in complex with jq1 (10.1021/CB5007344 )
• 4UIX: n-terminal bromodomain of human brd4 with 7-(3,4-dimethoxyphenyl)-n- (1,1-dioxo-1-thian-4-yl)-5-methyl-4-oxo-4h,5h-thieno-3,2-c-pyridine- 2- carboxamide (10.1021/ACS.JMEDCHEM.5B00256 )
• 4UIY: n-terminal bromodomain of human brd4 with n-(1,1-dioxo-1-thian-4-yl)- 5-methyl-4-oxo-7-3-(trifluoromethyl)phenyl-4h,5h-thieno-3,2-c- pyridine-2-carboximidamide (10.1021/ACS.JMEDCHEM.5B00256 )
• 4UIZ: n-terminal bromodomain of human brd4 with 7-(3,4- dimethoxyphenyl)-2-(4-methanesulfonylpiperazine-1-carbonyl) -5-methyl-4h,5h-thieno-3,2-c-pyridin-4-one (10.1021/ACS.JMEDCHEM.5B00256 )
• 4UYD: n-terminal bromodomain of human brd4 with 1,3-dimethyl-2- oxo-2,3-dihydro-1h-1,3-benzodiazole-5-carboxamide (10.1021/ML5002932 )
• 4WHW: direct photocapture of bromodomains using tropolone chemical probes
• 4WIV: crystal structure of the first bromodomain of human brd4 in complex with a novel inhibitor umb32 (n-tert-butyl-2-[4-(3,5-dimethyl-1,2- oxazol-4-yl) phenyl]imidazo[1,2-a]pyrazin-3-amine) (10.1021/JM501120Z )
• 4X2I: discovery of benzotriazolo diazepines as orally-active inhibitors of bet bromodomains: crystal structure of brd4 with cpi-13 (10.1021/ML500411H )
• 4XY9: crystal structure of the first bromodomain of human brd4 in complex with a 2-amine-9h-purine ligand (10.1021/JM501893K )
• 4XYA: crystal structure of the first bromodomain of human brd4 in complex with a 2-amine-9h-purine ligand (10.1021/JM501893K )
• 4YH3: crystal structure of human brd4(1) in complex with 4-[(2e)-3-(4- methoxyphenyl)-2-phenylprop-2-enoyl]-3,4-dihydroquinoxalin-2(1h)-one (compound 19a) (10.1016/J.BMCL.2015.04.107 )
• 4YH4: crystal structure of human brd4(1) in complex with 4-[(5- phenylpyridin-3-yl)carbonyl]-3,4-dihydroquinoxalin-2(1h)-one (compound 19d) (10.1016/J.BMCL.2015.04.107 )
• 4Z1Q: crystal structure of the first bromodomain of human brd4 bound to benzotriazolo-diazepine scaffold (10.1021/ML500411H )
• 4Z1S: crystal structure of the first bromodomain of human brd4 with benzotriazolo-diazepine scaffold (10.1021/ML500411H )
• 4Z93: brd4 bromodomain 2 in complex with gamma-carboline-containing compound, number 18. (10.1021/ACS.JMEDCHEM.5B00613 )
• 4ZC9: crystal structure of the brd4a/db-2-190 complex (10.1126/SCIENCE.AAB1433 )
• 4ZW1: crystal structure of hbrd4 in complex with bl-bi06 reveals a novel synthesized inhibitor that induces beclin1-independent/atg5-dependent autophagic cell death in breast cancer
• 5A5S: nn-terminal bromodomain of human brd4 with 5-5- methoxypyridin-3-yl-3-methyl-8-piperidin-4-ylamino-1,2- dihydro-1,7-naphthyridin-2-one (10.1021/ACS.JMEDCHEM.5B00772 )
• 5A85: n-terminal bromodomain of human brd4 with 8-(3r,4r)-3- (cyclohexylmethoxy)piperidin-4-ylamino-3-methyl-1,2-dihydro- 1,7-naphthyridin-2-one (10.1021/ACS.JMEDCHEM.5B00773 )
• 5ACY: n-terminal bromodomain of human brd4 with 1-(2r,4s)-2- methyl-4-(phenylamino)-6-4-(piperidin-1-ylmethyl)phenyl- 1,2,3,4-tetrahydroquinolin-1-yl-ethan-1-one (10.1084/JEM.20151271 )
• 5AD2: bivalent binding to bet bromodomains (10.1038/NCHEMBIO.2210 )
• 5AD3: bivalent binding to bet bromodomains (10.1038/NCHEMBIO.2210 )
• 5BT4: crystal structure of brd4 first bromodomain in complex with sgc-cbp30 chemical probe
• 5CFW: selective pharmacological inhibition of the creb binding protein bromodomain regulates inflammatory cytokines in macrophages and rgs4 in neurons (10.1016/J.CHEMBIOL.2015.10.013 )
• 5COI: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CP5: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CPE: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CQT: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CRM: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CRZ: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CS8: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CTL: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5CY9: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5D0C: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5D24: first bromodomain of brd4 bound to inhibitor xd26 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D25: first bromodomain of brd4 bound to inhibitor xd27 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D26: first bromodomain of brd4 bound to inhibitor xd28 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3H: first bromodomain of brd4 bound to inhibitor xd29 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3J: first bromodomain of brd4 bound to inhibitor xd33 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3L: first bromodomain of brd4 bound to inhibitor xd35 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3N: first bromodomain of brd4 bound to inhibitor xd40 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3P: first bromodomain of brd4 bound to inhibitor xd41 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3R: first bromodomain of brd4 bound to inhibitor xd42 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3S: first bromodomain of brd4 bound to inhibitor xd44 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5D3T: first bromodomain of brd4 bound to inhibitor xd47 (10.1021/ACS.JMEDCHEM.5B01267 )
• 5DLX: first domain of human bromodomain brd4 in complex with inhibitor n-{3- [4-(3-chlorophenyl)piperazin-1-yl]propyl}-1-{3-methyl-[1,2, 4]triazolo[4,3-b]pyridazin-6-yl}piperidine-4-carboxamide (10.1021/ACSCHEMBIO.6B00286 )
• 5DLZ: first domain of human bromodomain brd4 in complex with inhibitor 4- [(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy]-n-({1-[(3-methylphe methyl]piperidin-4-yl}methyl)butanamide (10.1021/ACSCHEMBIO.6B00286 )
• 5DW2: x-ray crystal structure of human brd4(bd1) in complex with rvx297 to 1.12 a resolution (10.1016/J.BBRC.2016.06.021 )
• 5DX4: crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand (10.1021/ACS.JMEDCHEM.5B01511 )
• 5E0R: crystal structure of the first bromodomain of brd4 in complex with ayc
• 5EGU: first domain of human bromodomain brd4 in complex with inhibitor 3- butyl-8-(6-butyl-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylsulfanylmethyl)-7-ethyl-3,7-dihydropurine-2,6-dione (10.1021/ACS.JMEDCHEM.5B01708 )
• 5EI4: first domain of human bromodomain brd4 in complex with inhibitor 8-(5- amino-1h-[1,2,4]triazol-3-ylsulfanylmethyl)-3-(4-chlorobenzyl)-7- ethyl-3,7-dihydropurine-2,6-dione (10.1021/ACS.JMEDCHEM.5B01708 )
• 5EIS: first domain of human bromodomain brd4 in complex with inhibitor 3-(4- chlorobenzyl)-7-ethyl-3,7-dihydropurine-2,6-dione (10.1021/ACS.JMEDCHEM.5B01708 )
• 5F5Z: crystal structure of the first bromodomain of human brd4 in complex with ma2-014 (10.1158/1535-7163.MCT-16-0568-T )
• 5F60: crystal structure of the first bromodomain of human brd4 in complex with sg3-014 (10.1158/1535-7163.MCT-16-0568-T )
• 5F61: crystal structure of the first bromodomain of human brd4 in complex with ma4-022-1 (10.1158/1535-7163.MCT-16-0568-T )
• 5F62: crystal structure of the first bromodomain of human brd4 in complex with ma4-022-2 (10.1158/1535-7163.MCT-16-0568-T )
• 5F63: crystal structure of the first bromodomain of human brd4 in complex with sg3-179 (10.1158/1535-7163.MCT-16-0568-T )
• 5FBX: crystal structure of the first bromodomain of human brd4 in complex with pnz5 isoxazole inhibitor
• 5H21: trimethoxy-ring inhibitor in complex with the first bromodomain of brd4 (10.1039/C7MD00083A )
• 5HCL: crystal structure of the first bromodomain of brd4 in complex with dma (10.1038/SREP42108 )
• 5HLS: crystal structure of the first bromodomain of human brd4 bound to cpi- 0610 (10.1021/ACS.JMEDCHEM.5B01882 )
• 5HM0: crystal structure of the first bromodomain of human brd4 bound to benzoisoxazoloazepine 3 (10.1021/ACS.JMEDCHEM.5B01882 )
• 5HQ5: crystal structure of fragment bound with brd4
• 5HQ6: crystal structure of fragment bound with brd4
• 5HQ7: crystal structure of fragment bound with brd4
• 5I80: brd4 in complex with cpd2 (n,n-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro- 1h-pyrrolo[2,3-c]pyridin-4-yl)benzamide) (10.1021/ACS.JMEDCHEM.6B00264 )
• 5I88: brd4 in complex with cpd4 ((e)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro- 1h-pyrrolo[2,3-c]pyridin-4-yl)-n,n-dimethylbenzamide) (10.1021/ACS.JMEDCHEM.6B00264 )
• 5IGK: crystal structure of the first bromodomain of human brd4 in complex with bromosporine (bsp) (10.1126/SCIADV.1600760 )
• 5JWM: bivalent bet bromodomain inhibition (10.1038/NCHEMBIO.2209 )
• 5KDH: crystal structure of the first bromodomain of human brd4 in complex with a dihydropyridopyrimidine scaffold inhibitor (10.1021/ACS.JMEDCHEM.6B01336 )
• 5KHM: the first bet bromodomain of brd4 bound to compound 13 in a bivalent manner (10.1021/ACS.JMEDCHEM.6B00070 )
• 5KJ0: crystal structure of the first bromodomain of human brd4 in complex with db-1-264-2 (10.1002/CMDC.201600502 )
• 5KU3: brd4 bromodomain in complex with cpd59 ((s)-1-(3-((2-fluoro-4-(1- methyl-1h-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7- dihydro-1h-pyrazolo[4,3-c]pyridin-5(4h)-yl)ethanone) (10.1021/ACS.JMEDCHEM.6B01022 )
• 5LJ1: n-terminal bromodomain of human brd4 with 8-(((3r,4r,5s)-3-((4,4- difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl- 5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1h)-one (10.1002/ANIE.201603928 )
• 5LJ2: n-terminal bromodomain of human brd4 with 5-(5-aminopyridin-3-yl)-8- (((3r,4r)-3-((1,1-dioxidotetrahydro-2h-thiopyran-4-yl)methoxy) piperidin-4-yl)amino)-3-methyl-1,7-naphthyridin-2(1h)-one (10.1002/ANIE.201603928 )
• 5LRQ: brd4 in complex with erk5 inhibitor xmd8-92 (10.1016/J.EJMECH.2019.05.057 )
• 5LUU: structure of the first bromodomain of brd4 with a pyrazolo[4,3- c]pyridin fragment (10.1021/ACSMEDCHEMLETT.6B00154 )
• 5M39: crystal structure of brd4 bromodomain 1 in complex with ligand 1 (10.1021/ACS.JMEDCHEM.7B00845 )
• 5M3A: crystal structure of brd4 bromodomain 1 in complex with ligand 2 (10.1021/ACS.JMEDCHEM.7B00845 )
• 5MKZ: n-terminal bromodomain of human brd4 with 4-chloro-2-methyl-5-(((3- methylthiophen-2-yl)methyl)amino)pyridazin-3(2h)-one (10.1021/ACS.JMEDCHEM.6B01566 )
• 5MLI: n-terminal bromodomain of human brd4 with 4-chloro-2-methyl-5- (methylamino)pyridazin-3(2h)-one (10.1021/ACS.JMEDCHEM.6B01566 )
• 5N2M: crystal structure of the first bromodomain of human brd4 in complex with a tetrahydroquinoline analogue
• 5NNC: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated histone 4 peptide (h3k9ac/k14ac) (10.1016/J.MOLCEL.2018.11.006 )
• 5NND: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated histone 4 peptide (h3k9ac/k14ac) (10.1016/J.MOLCEL.2018.11.006 )
• 5NNE: crystal structure of the first bromodomain of human brd4 in complex with a diacetylated top2a peptide (k1201ac/k1204ac) (10.1016/J.MOLCEL.2018.11.006 )
• 5NNF: crystal structure of the first bromodomain of human brd4 in complex with an acetylated baz1b peptide (k221ac) (10.1016/J.MOLCEL.2018.11.006 )
• 5NNG: crystal structure of the first bromodomain of human brd4 in complex with an acetylated srpk1 peptide (k585ac) (10.1016/J.MOLCEL.2018.11.006 )
• 5O97: crystal structure of human brd4(1) bromodomain in complex with jrmbr4106
• 5OVB: crystal structure of human brd4(1) bromodomain in complex with dr46 (10.1021/ACSCENTSCI.7B00401 )
• 5OWM: crystal structure of human brd4(1) bromodomain in complex with ut48 (10.1021/ACSCENTSCI.7B00401 )
• 5OWW: crystal structure of human brd4(1) bromodomain in complex with ut22b (10.1021/ACSCENTSCI.7B00401 )
• 5T35: the protac mz1 in complex with the second bromodomain of brd4 and pvhl:elonginc:elonginb (10.1038/NCHEMBIO.2329 )
• 5TI2: crystal structure of the first bromodomain of human brd4 in complex with inhibitor 7635936 (10.1021/ACSOMEGA.7B00553 )
• 5TI3: crystal structure of the first bromodomain of human brd4 in complex with inhibitor 17503468 (10.1021/ACSOMEGA.7B00553 )
• 5TI4: crystal structure of the first bromodomain of human brd4 in complex with inhibitor 8841871 (10.1021/ACSOMEGA.7B00553 )
• 5TI5: crystal structure of the first bromodomain of human brd4 in complex with inhibitor 8841880 (10.1021/ACSOMEGA.7B00553 )
• 5TI6: crystal structure of the first bromodomain of human brd4 in complex with inhibitor 8841881 (10.1021/ACSOMEGA.7B00553 )
• 5TI7: crystal structure of the first bromodomain of human brd4 in complex with inhibitor 17528462 (10.1021/ACSOMEGA.7B00553 )
• 5U28: brd4 first bromodomain (bd1) in complex with dual pi3 kinase inhibitor sf2523 (10.1073/PNAS.1613091114 )
• 5U2C: brd4 second bromodomain (bd2) in complex with dual pi3 kinase (pi3k) inhibitor sf2558ha (10.1073/PNAS.1613091114 )
• 5U2E: brd4 first bromodomain (bd1) in complex with dual pi3 kinase (pi3k) inhibitor sf2535 (10.1073/PNAS.1613091114 )
• 5U2F: brd4 first bromodomain (bd1) in complex with dual pi3 kinase (pi3k) inhibitor sf2558ha (10.1073/PNAS.1613091114 )
• 5UEO: brd4_bd2_a-1395017
• 5UEP: brd4_bd2_a-581577
• 5UEQ: brd4_bd2_a-1390146
• 5UER: brd4_bd2_a-1359930
• 5UES: brd4_bd2_a-1344772
• 5UET: brd4_bd2_a-1308586
• 5UEU: brd4_bd2_a-1107604 (10.1021/ACS.JMEDCHEM.7B00017 )
• 5UEV: brd4_bd2_a-556343
• 5UEX: brd4_bd2_a-1497627 (10.1021/ACS.JMEDCHEM.7B00017 )
• 5UEY: brd4_bd2_a-1412838 (10.1021/ACS.JMEDCHEM.7B00017 )
• 5UEZ: brd4_bd2_a-1342843 (10.1021/ACS.JMEDCHEM.7B00017 )
• 5UF0: brd4_bd2-a-35165 (10.1021/ACS.JMEDCHEM.7B00017 )
• 5ULA: crystal structure of the first bromodomain of human brd4 in complex with cyclic vinylogous amide inhibitor ms402 (10.1073/PNAS.1615601114 )
• 5UOO: brd4 bromodomain 2 in complex with cd161 (10.1021/ACS.JMEDCHEM.7B00193 )
• 5UVS: brd4_bd2_a-1406537
• 5UVT: brd4_bd2_a-1454056
• 5UVU: brd4_bd2_a-1461028
• 5UVV: brd4 bromodomain 2 with a-1457066
• 5UVW: brd4_bromodomain1-a1376855
• 5UVX: brd4 bromodomain 2 with a-1359643
• 5UVY: brd4 bromodomain 2 with a-1349391
• 5UVZ: brd4 bromodomain 2 with a-1354689
• 5V67: crystal structure of the first bromodomain of human brd4 in complex with volasertib
• 5VBO: crystal structure of the first bromodomain of human brd4 in complex with lrrk2-in-1
• 5VBP: crystal structure of the first bromodomain of human brd4 in complex with ro3280
• 5VOM: benzopiperazine bet bromodomain inhibitor in complex with bd1 of brd4 (10.1021/ACSMEDCHEMLETT.7B00191 )
• 5VZS: brd4-bd1 in complex with cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1h- pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)-n-methyl-1-(tetrahydro- 2h-pyran-4-yl)-1,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5- carboxamide)
• 5W55: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg048
• 5WA5: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor xmd11-50 (10.1021/ACSCHEMBIO.7B00638 )
• 5WMA: n-terminal bromodomain of brd4 in complex with plx5981 (10.1158/2159-8290.CD-17-0902 )
• 5WMD: n-terminal bromodomain of brd4 in complex with otx-015 (10.1158/2159-8290.CD-17-0902 )
• 5WMG: n-terminal bromodomain of brd4 in complex with otx-015 (10.1158/2159-8290.CD-17-0902 )
• 5WUU: complex structure of the first bromodomain of brd4 with an inhibitor that containing a 2h-chromen-2-one ring (10.1016/J.BMCL.2017.03.012 )
• 5XHY: brd4 bound with compound bdi1
• 5XI2: brd4 bound with compound bdi2
• 5XI3: brd4 bound with compound bdi3
• 5XI4: brd4 bound with compound bdi4
• 5Y1Y: complex structure of nitroxoline with the first bromodomain of brd4 (10.1039/C7OB02369C )
• 5Y8C: crystal structure analysis of the brd4 (10.1021/ACS.JMEDCHEM.8B00103 )
• 5Y8W: crystal structure analysis of the brd4 (10.1021/ACS.JMEDCHEM.8B00103 )
• 5Y8Y: crystal structure analysis of the brd4 (10.1021/ACS.JMEDCHEM.8B00103 )
• 5Y8Z: crystal structure analysis of the brd4 (10.1021/ACS.JMEDCHEM.8B00103 )
• 5Y93: crystal structure analysis of the brd4 (10.1021/ACS.JMEDCHEM.8B00103 )
• 5Y94: crystal structure analysis of the brd4 (10.1021/ACS.JMEDCHEM.8B00103 )
• 5YOU: crystal structure of brd4-bd1 bound with hjp64
• 5YOV: crystal structure of brd4-bd1 bound with hjp126 (10.1016/J.EJMECH.2018.02.070 )
• 5YQX: crystal structure analysis of the brd4 (10.1016/J.EJMECH.2018.04.034 )
• 5Z1R: crystal structure analysis of the brd4 (10.1021/ACSMEDCHEMLETT.8B00003 )
• 5Z1S: crystal structure analysis of the brd4(1) (10.1021/ACSMEDCHEMLETT.8B00003 )
• 5Z1T: crystal structure analysis of the brd4(1) (10.1021/ACSMEDCHEMLETT.8B00003 )
• 5Z5T: the first bromodomain of brd4 with compound bdf-2141 (10.1038/S41389-018-0093-Z )
• 5Z5U: the first bromodomain of brd4 with compound bdf-2254 (10.1038/S41389-018-0093-Z )
• 5Z5V: the first bromodomain of brd4 with compound bdf-1253 (10.1038/S41389-018-0093-Z )
• 5Z8G: brd4 bromodomain 1 with an inhibitor
• 5Z8R: brd4 bromodomain 1 with an inhibitor
• 5Z8Z: brd4 bromodomain 1 with an inhibitor
• 5Z90: brd4 bromodomain 1 with an inhibitor
• 5Z9C: solution nmr structures of brd4 first bromodomain with small compound mmqo (10.1128/JVI.02056-17 )
• 5Z9K: brd4 bromodomain 1 with an inhibitor
• 6AFR: crystal structure of the first bromodomain of human brd4 in complex with 5-((4-fluoro-1h-imidazol-1-yl)methyl)quinolin-8-ol (10.1016/J.EJMECH.2018.11.018 )
• 6AJV: crystal structure of brd4 in complex with isoliquiritigenin and dmso (cocktail no. 3) (10.1111/FEBS.14736 )
• 6AJW: crystal structure of brd4 in complex with dmso (cocktail no. 4) (10.1111/FEBS.14736 )
• 6AJX: crystal structure of brd4 in complex with isoliquiritigenin in the absence of dmso (10.1111/FEBS.14736 )
• 6AJY: crystal structure of brd4 in complex with 2',4'-dihydroxy-2- methoxychalcone (10.1111/FEBS.14736 )
• 6AJZ: joint nentron and x-ray structure of brd4 in complex with colchicin (10.1111/FEBS.14736 )
• 6BN7: crystal structure of ddb1-crbn-brd4(bd1) complex bound to dbet23 protac. (10.1038/S41589-018-0055-Y )
• 6BN8: crystal structure of ddb1-crbn-brd4(bd1) complex bound to dbet55 protac. (10.1038/S41589-018-0055-Y )
• 6BN9: crystal structure of ddb1-crbn-brd4(bd1) complex bound to dbet70 protac (10.1038/S41589-018-0055-Y )
• 6BNB: crystal structure of ddb1-crbn-brd4(bd1) complex bound to dbet57 protac (10.1038/S41589-018-0055-Y )
• 6BOY: crystal structure of ddb1-crbn-brd4(bd1) complex bound to dbet6 protac. (10.1038/S41589-018-0055-Y )
• 6C7Q: brd4 bd2 in complex with compound ce277 (10.1021/ACS.JMEDCHEM.8B00483 )
• 6C7R: brd4 bd1 in complex with compound cf53 (10.1021/ACS.JMEDCHEM.8B00483 )
• 6CD4: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg046 (10.1021/ACSCHEMBIO.7B00638 )
• 6CD5: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor xmd17-26 (10.1021/ACSCHEMBIO.7B00638 )
• 6CIS: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg047 (10.1021/ACSCHEMBIO.7B00638 )
• 6CIY: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg069 (10.1021/ACSCHEMBIO.7B00638 )
• 6CJ1: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg071 (10.1021/ACSCHEMBIO.7B00638 )
• 6CJ2: crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg056 (10.1021/ACSCHEMBIO.7B00638 )
• 6CKR: crystal structure of brd4 with qc4956 (10.1016/J.BMCL.2018.04.016 )
• 6CKS: crystal structure of brd4 with qc4956 (10.1016/J.BMCL.2018.04.016 )
• 6CZU: brd4(bd1) complexed with 3219 (10.1021/ACS.JMEDCHEM.8B00666 )
• 6CZV: brd4(bd1) complexed with 2759 (10.1021/ACS.JMEDCHEM.8B00666 )
• 6DJC: crystal structure of human bromodomain-containing protein 4 (brd4) bromodomain with ms645 (10.1073/PNAS.1720000115 )
• 6DL2: brd4 bromodomain 1 in complex with hyb157 (10.1021/ACS.JMEDCHEM.8B00506 )
• 6DMJ: a multiconformer ligand model of inhibitor 53w bound to creb binding protein bromodomain (10.1021/ACS.JMEDCHEM.8B01292 )
• 6DML: a multiconformer ligand model of 3,5 dimethylisoxaxole bound to the bromodomain of human brd4 (10.1021/ACS.JMEDCHEM.8B01292 )
• 6DUV: crystal structure of the second bromodomain of human brd4 in complex with ms417 inhibitor
• 6E4A: crystal structure of human brd4(1) in complex with cn750 (10.1016/J.BMCL.2018.08.039 )
• 6FFD: human brd4 c-terminal bromodomain with 1-(4-(3-methylbenzyl)-3,4- dihydroquinoxalin-1(2h)-yl)ethanone
• 6FNX: first domain of human bromodomain brd4 in complex with inhibitor f1 (10.1021/ACS.JMEDCHEM.8B00653 )
• 6FO5: first domain of human bromodomain brd4 in complex with inhibitor #17 (10.1021/ACS.JMEDCHEM.8B00653 )
• 6FSY: crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand (10.1016/J.BMC.2018.05.003 )
• 6FT3: crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand (10.1016/J.BMC.2018.05.003 )
• 6FT4: crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand (10.1016/J.BMC.2018.05.003 )
• 6G0D: brd4 (bd1) in complex with apsc-derived ligands (e.g. ly294002) (10.26434/CHEMRXIV.11472618 )